VERATRUM PHARMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 533,028 | 535,335 | 602,192 | 641,484 | 460,724 | 417,370 | 423,464 | 359,704 |
| Profit before tax | 112,358 | 135,692 | 98,249 | 157,328 | 46,704 | 32,653 | 259,599 | 8,859 |
| Net profit | 95,560 | 115,626 | 68,905 | 134,150 | 39,790 | 28,153 | 220,551 | 7,481 |
| Equity | 998,566 | 1,114,192 | 1,183,097 | 1,317,247 | 1,357,037 | 1,385,190 | 1,605,741 | 1,613,221 |
| Liabilities | 105,478 | 110,356 | 179,109 | 227,078 | 69,727 | 71,609 | 65,314 | 87,243 |
| Non-current assets | 432,038 | 424,011 | 39,446 | 55,603 | 41,473 | 32,858 | 24,895 | 17,971 |
| Current assets | 671,538 | 799,443 | 1,322,527 | 1,487,943 | 1,383,480 | 1,422,469 | 1,644,431 | 1,681,650 |
| Total assets | 1,103,576 | 1,223,454 | 1,361,973 | 1,543,546 | 1,424,953 | 1,455,327 | 1,669,326 | 1,699,621 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 72,301 | 101,588 | 67,703 |
| Social insurance contributions | - | - | - | - | - | 14,404 | 16,722 | 18,278 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -8.6% | +0.4% | +12.5% | +6.5% | -28.2% | -9.4% | +1.5% | -15.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 8.7% | 9.5% | 5.1% | 8.7% | 2.8% | 1.9% | 13.2% | 0.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 9.6% | 10.4% | 5.8% | 10.2% | 2.9% | 2.0% | 13.7% | 0.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 17.9% | 21.6% | 11.4% | 20.9% | 8.6% | 6.7% | 52.1% | 2.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 21.1% | 25.3% | 16.3% | 24.5% | 10.1% | 7.8% | 61.3% | 2.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 66,629 | 73,839 | 76,066 | 80,186 | 95,323 | 71,550 | 70,577 | 59,951 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
VERATRUM PHARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-28 | 2026-08-31 | 979.00 |
| 2026-08-27 | 2026-08-27 | 1308.68 |
| 2026-08-26 | 2026-08-26 | 1520.41 |
| 2026-08-23 | 2026-08-23 | 1520.41 |
| 2026-08-19 | 2026-08-19 | 1520.41 |
| 2026-07-23 | 2026-07-26 | 2.63 |
| 2026-07-19 | 2026-07-20 | 1520.27 |
| 2026-07-16 | 2026-07-17 | 1520.27 |
| 2026-06-11 | 2026-06-14 | 0.39 |
| 2026-05-19 | 2026-06-08 | 0.39 |
| 2026-05-17 | 2026-05-18 | 629.97 |
| 2022-12-16 | 2023-01-15 | 0.11 |
| 2022-11-21 | 2022-12-14 | 0.11 |
| 2022-11-17 | 2022-11-18 | 0.11 |
| 2022-10-18 | 2022-11-14 | 0.11 |
| 2022-09-16 | 2022-10-11 | 0.11 |
| 2022-08-23 | 2022-09-14 | 0.11 |
| 2022-07-25 | 2022-08-10 | 0.11 |
| 2022-05-17 | 2022-05-26 | 36.43 |
VERATRUM PHARMA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-08-28 | 2026-08-31 | 1989.0 |
| 2026-08-12 | 2026-08-19 | 0.27 |
| 2026-08-02 | 2026-08-03 | 2002.18 |
| 2026-04-01 | 2026-04-27 | 4.68 |
| 2026-03-29 | 2026-03-31 | 2502.08 |
| 2026-02-21 | 2026-02-21 | 599.0 |
| 2025-11-28 | 2025-12-31 | 1.93 |
| 2025-10-02 | 2025-11-25 | 1.26 |
| 2025-09-26 | 2025-09-26 | 6.82 |
| 2025-09-01 | 2025-09-25 | 1.82 |
| 2025-08-28 | 2025-08-31 | 0.91 |
| 2025-07-29 | 2025-08-18 | 2.58 |
| 2025-07-28 | 2025-07-28 | 3187.0 |
| 2025-06-29 | 2025-06-30 | 732.87 |
| 2025-06-28 | 2025-06-28 | 1732.4 |
| 2025-06-20 | 2025-06-20 | 2001.06 |
| 2025-06-19 | 2025-06-19 | 2000.52 |
| 2025-05-30 | 2025-05-30 | 1321.84 |
| 2025-05-29 | 2025-05-29 | 1320.58 |
| 2024-11-01 | 2024-11-18 | 888.68 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
VERATRUM PHARMA, UAB (code 300584679) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €359.7K and net profit of €7.5K, which corresponded to a profit margin of 2.1%. Revenue declined by 15.1% year on year and was 13.8% lower than two years earlier, indicating a softer sales trend after a stronger 2024. The 2023–2025 trajectory shows revenue rising slightly from €417.4K in 2023 to €423.5K in 2024, then falling in 2025, while net profit moved from €28.2K to €220.6K and then back to €7.5K. At the end of 2025, total assets stood at €1.70M, equity at €1.61M and liabilities at €87.2K. The balance sheet remained strongly equity-funded, with an equity ratio of 94.9% and debt-to-equity of 0.05. Asset turnover was 0.21x. Revenue per employee was €60.0K and profit per employee €1.2K.